Area of research
Surgery · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, and Esophageal Cancer Research and Treatment.
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors
<i>Escherichia coli</i> –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum‐based chemotherapy for locally advanced (Stage <scp>III</scp>) urothelial cancer
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial